Abstract
Clinical immunolocalization has been attempted by others with an anti-Thomsen-Friedenreich antigen (TF-Ag) mAb that bound both alpha- and beta-linked TF-Ag. In this report, 124 I-labeled mAb JAA-F11 specific for alpha-linked TF-Ag showed higher tumor specificity in in vivo micro-positron emission tomography (micro-PET) of the mouse mammary adenocarcinoma line, 4T1, showing no preferential uptake by the kidney. Labeled product remained localized in the tumor for at least 20 days. Glycan array analysis showed structural specificity of the antibody.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / diagnostic imaging*
-
Adenocarcinoma / metabolism
-
Animals
-
Antibodies, Monoclonal* / immunology
-
Antibodies, Monoclonal* / pharmacokinetics
-
Antibody Specificity
-
Antigens, Tumor-Associated, Carbohydrate / immunology*
-
Carbohydrate Sequence
-
Cell Line, Tumor
-
Female
-
Immunoconjugates / immunology
-
Immunoconjugates / pharmacokinetics
-
Iodine Radioisotopes* / pharmacokinetics
-
Mammary Neoplasms, Experimental / diagnostic imaging*
-
Mammary Neoplasms, Experimental / metabolism
-
Mice
-
Mice, Inbred BALB C
-
Molecular Sequence Data
-
Polysaccharides / immunology
-
Polysaccharides / pharmacokinetics
-
Positron-Emission Tomography
Substances
-
Antibodies, Monoclonal
-
Antigens, Tumor-Associated, Carbohydrate
-
Immunoconjugates
-
Iodine Radioisotopes
-
Polysaccharides
-
Thomsen-Friedenreich antigen